Prognostic factors for advanced-stage human immunodeficiency virus-associated classical hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy. Cancer
Castillo et al. aimed at identifying predictive and prognostic factors in patients with HIV-associated classical Hodgkin Lymphoma (HL) receiving a combination of chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine; ABVD) and antiretroviral therapy. Patients experienced high overall response rates to therapy of 91% and high 5-year progression-free survival and overall survival rates of 69% and 78%, respectively. A CD4-positive count
The study supports the finding that HIV-infected patients with HL should receive standard doses of ABVD and underscores the prognostic value of the CD4-positive cell count at HL diagnosis.